171 Oyster Point Boulevard
South San Francisco
About Surrozen, Inc.
Repair. Restore. Renew
Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway. Surrozen is at pre-clinical stage, and anticipates its first clinical trials will be underway in 2022. Surrozen (SRZN) became publicly traded in August of 2021.
Our inclusive and pioneering culture creates a sense of belonging, impact, adventure and fun. Join us and Collaborate, Lead, Innovate Motivate and be Brave, Open and Nurturing at Surrozen!
Surrozen offers a competitive total rewards package that includes:
- Health and welfare benefits
- Generous vacation, sick leave, and company paid holidays
- 401k match
- Company sponsored events, adventures and weekly lunches
- Bring your dog to work Fridays
Craig Parker is the Chief Executive Officer at Surrozen. Their research in the Wnt pathway and proteins identified these are critical to maintaining tissues in our body and are found in tissues as diverse as the lung, intestine, liver, sensory hair cells, and the eye.
New Company Values
A committee of Surrozen employees put their heads together and came up with our new company values. In every project we take on these 7 keys words are at the forefront. CLIMB ON!!!
31 articles with Surrozen, Inc.
Surrozen's ethos is “CLIMB ON”. This catchy and focus-appropriate acronym stands for Collaborate, Lead, Innovate, Motivate and be Brave, Open and Nurturing.
Surrozen, Inc. today announced that Craig Parker, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 a.m. ET on Monday, November 22.
Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced today that data from its liver disease program, including preclinical studies of SZN-043 showing improved liver metabolic function, were presented during The Liver Meeting 2021.
Surrozen, Inc. today announced that Craig Parker, Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference at 4:40 p.m. ET on Tuesday, November 16.
Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week
Surrozen, Inc. announced that data from its inflammatory bowel disease program, including preclinical studies of SZN-1326 showing colonic mucosal healing in an acute injury model were presented during the 2021 United European Gastroenterology Week.
Surrozen Inc. today announced that Elizabeth “Liz” Nguyen has been appointed as Vice President and Head of Human Resources (HR).
Surrozen, Inc., a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced the completion of its business combination with Consonance-HFW Acquisition Corp., a special purpose acquisition company sponsored by entities affiliated with Consonance Capital Management.
Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced that Craig Parker, chief executive officer, will provide a company overview and a business update at Canaccord Genuity’s 41st Annual Growth Conference at 9:30 a.m. ET on Thursday, August 12.
Surrozen Presents New Data Demonstrating Superior Activity of SZN-1326 in Preclinical Inflammatory Bowel Disease Models at 16th Congress of the European Crohn’s and Colitis Organization
Surrozen Inc. announced today that new data from its inflammatory bowel disease (IBD) program, including preclinical studies of SZN-1326 showing superior activity compared to therapeutics currently used in treatment, were presented during the 16 th Congress of the European Crohn’s and Colitis Organisation.
Surrozen Presents Data at 2021 International Liver Conference for Wnt-Modulating Antibody SZN-043Company to advance SZN-043 toward first-in-human clinical studies in 2022
Surrozen Inc. announced today that data from preclinical studies of SZN-043 were presented during The Digital International Liver Congress™ 2021 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL).
Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Biology Conference: Fundamental Mechanisms and Translational Applications
Surrozen Inc. announced today that data from preclinical studies were presented in four oral Abstract Flash Talk presentations during The Liver Biology Conference.
Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced today that data from preclinical studies of its two lead Wnt-modulating antibody programs were presented in six oral and poster presentations during Digestive Disease Week 2021 .
5/7/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Surrozen Strengthens Board of Directors with Appointments of Mace Rothenberg, M.D., and Christopher Chai
Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced the addition of Mace Rothenberg, M.D., and Christopher Chai to its Board of Directors.
4/21/2021Investment funds continue springing up into life sciences companies across the globe. Here’s where the money’s being planted this week.
Surrozen and Consonance-HFW Acquisition Corp. Announce Business Combination, Creating Publicly Listed Leader in Wnt Biology and Tissue Regeneration
Surrozen expects to receive approximately $212 million in gross proceeds from the business combination, including $120 million from a committed PIPE financing and $92 million cash in trust from Consonance-HFW. Lead investors in the PIPE were a U.S.-based, healthcare-focused fund and Consonance Capital Management, with participation from other leading life sciences-dedicated funds and existing Surrozen investors including The Column Group.
Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, announced that Craig Parker, president and chief executive officer of Surrozen, will be presenting at the Stifel 2020 Virtual Healthcare Conference.
Surrozen Awarded NIH Grant to Support Development of SZN-043, a Liver-Specific Regenerative Antibody, for the Treatment of Severe Alcoholic Hepatitis
Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, has been awarded an NIH grant to support development of SZN-043, a novel liver-targeted regenerative antibody.
Craig Parker, CEO of Surrozen, to present Surrozen’s advancements in regenerative medicine